Unilateral generalized morphea is a rare variant of localized scleroderma

European Journal of Medical Research

Volumn 11, Issue 4, 2006, Pages 152-156

  Appelhans, C ^a   Breuckmann, F ^a   Gambichler, T ^a   Brockmeyer, N H ^a   Altmeyer, P ^a   Kreuter, Alexander ^a  

^a RUHR UNIVERSITY BOCHUM   (Germany)

Author keywords

Fibrosis; Localized scleroderma; Low dose methotrexate; Pulsed high dose corticosteroids; Unilateral generalized morphea

Indexed keywords

ANTINUCLEAR ANTIBODY; CEFTRIAXONE; CHLOROQUINE; CORTICOSTEROID; EMOLLIENT AGENT; GLUCOCORTICOID; HISTONE H1; HISTONE H3; METHOTREXATE; PREDNISONE; PROCOLLAGEN TYPE 3 AMINOPROPEPTIDE; RHEUMATOID FACTOR; SMOOTH MUSCLE ANTIBODY;

ADOLESCENT; ADULT; ANTIBODY DETECTION; ANTIGEN ANTIBODY COMPLEX; ARTICLE; CASE REPORT; CLINICAL FEATURE; DERMIS; DRUG MEGADOSE; DRUG PULSE THERAPY; FAMILY HISTORY; FEMALE; GENETIC VARIABILITY; HISTOPATHOLOGY; HUMAN; HYPERPIGMENTATION; LOW DRUG DOSE; LYMPHATIC DRAINAGE; MORPHEA; MUSCLE ATROPHY; PHOTOTHERAPY; PHYSIOTHERAPY; RAYNAUD PHENOMENON; SKIN ATROPHY; SKIN DEFECT; SUBCUTANEOUS FAT; THERAPY RESISTANCE; TREATMENT FAILURE; TREATMENT OUTCOME; ULTRAVIOLET A RADIATION;

ADOLESCENT; ADULT; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; FEMALE; GLUCOCORTICOIDS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; METHOTREXATE; PREDNISOLONE; PULSE THERAPY, DRUG; SCLERODERMA, LOCALIZED; TREATMENT OUTCOME;

EID: 33646727557     PISSN: 09492321     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Steen VD, Medsger TA Jr. Epidemiology and natural history of systemic sclerosis. Rheum Dis Clin North Am 1990;16:1-10.
2. Perez MI, Kohn SR. Systemic sclerosis. J Am Acad Dermatol 1993;28:525-47.
3. Wuthrich RC, Roenigk HH, Steck WD. Localized scleroderma. Arch Dermatol 1975;111:98-100.
4. Ghersetich I, Teofoli P, Benci M, Innocenti S, Lotti T. Localized scleroderma. Clin Dermatol 1994;12:237-42.
5. Peterson LS, Nelson AM, Su WP. Classification of morphea (localized scleroderma). Mayo Clin Proc 1995;70:1068-76.
6. Falanga V, Medsger TA Jr, Reichlin M, Rodnan GP. Linear scleroderma: clinical spectrum, prognosis and laboratory abnormalities. Ann Intern Med 1986;104:849-57.
7. Emery H. Pediatric scleroderma. Semin Cutan Med Surg 1998;17:41-7.
8. Nagai Y, Hattori T, Ishikawa O. Unilataral generalized morphea in childhood. J Dermatol 2002; 29:435-438.
9. Tuffanelli DL. Localized scleroderma. Semin Cutan Med Surg 1998;17:27-33.
10. Nelson AM. Localized forms of scleroderma, including morphea, linear scleroderma, and eosinophilic fasciitis. Curr Opin Rheumatol 1996;8:473-6.
11. Russell DC, Maloney A, Muir AL. Progressive generalized scleroderma: respiratory failure from primary chest wall involvement. Thorax 1981;36:219-20.
12. Daoud MS, Su WP, Leiferman KM, Perniciaro C. Bullous morphea: clinical, pathologic, and immunopathologic evaluation of thirteen cases. J Am Acad Dermatol 1994; 30:937-43.
13. Jablonska S, Blaszczyk M. Scleroderma-like disorders. Semin Cutan Med Sug 1998;17:65-76.
14. Person JR, Su WP. Subcutaneous morphoea: a clinical study of sixteen cases. Br J Dermatol 1979;100:371-80.
15. Diaz-Perez JL, Connolly SM, Winkelmann RK. Disabling pansclerotic morphea of children. Arch Dermatol 1980; 116:169-73.
16. Cardozo TJ. Eosinophilic fasciitis. Dermatol Online J 2003;9:33.
17. Su WP, Person JR. Morphea profunda. A new concept and a histopathologic study of 23 cases Am J Dermatopathol 1981;3:251-60.
18. Fleischmajer R, Nedwich A. Generalized morphea. Histology of the dermis and subcutaneous tissue. Arch Dermatol 1972;106:509-14.
19. Blann AD, Illingworth K, Jayson MIV. Mechanisms of endothelial cell damage in systemic sclerosis and Raynaud's phenomenon. J Rheumatol 1993;20:1325-30.
20. Rose NR, Leskovsek N. Scleroderma: immunopathogenesis and treatment. Immunol Today 1998;19:499-501.
21. Mauch C, Eckes B, Hunzelmann N, et al. Control of fibrosis in systemic scleroderma. J Invest Dermatol 1993;100:92-6.
22. Ferrarini M, Stehen VD, Medsger TA, Whiteside TL. Functional and phenotypic analysis of T lymphocytes cloned from the skin of patients with systemic sclerosis. Clin Exp Immunol 1990;79:346-52.
23. Scaletti C, Vultaggio A, Bonifacio S, et al. Th2-orientated profile of male offspring T cells present in women with systemic sclerosis and reactive with maternal major histocompatibility complex antigens. Arthrit Rheum 2002; 46:445-50.
24. Giacomelli R, Cipriani P, Fulminis A, et al. Circulating gamma/delta T lymphocytes from systemic sclerosis (SSc) patients display a T helper (Th) 1 polarization. Clin Exp Immunol 2001;125:310-5.
25. Sato S, Fujimoto M, Kikuchi K, Ihn H, Tamaki K, Takehara K. Soluble CD4 and CD8 in serum from patients with localized scleroderma. Arch Dermatol Res 1996;288: 358-362.
26. Ihn H, Yazawa N, Kubo M, et al. Circulating Levels of soluble CD30 are increased in patients with localized scleroderma and correlated with serological and clinical features of the disease. J Rheumatol 2000; 27:698-702.
27. Heickendorff L, Zachariae H, Bjerring P, Halkier-Sorensen L, Sondergaard K. The use of serologic markers for collagen synthesis and degradation in systemic sclerosis. J Am Acad Dermatol 1995;32:584-8.
28. Blaszczyk M, Janniger CK, Jablonska S. Childhood scleroderma and its peculiarities. Cutis 1996;58:141-152.
29. Blaszczyk M, Krysicka-Janiger CK, Jablonska S. Primary atrophic profound linear scleroderma. Dermatology 2000;200:63-66.
30. Torok E, Ablonczy E. Morphoea in children. Clin Exp Dermatol 1986;11:607-12.
31. Soma Y, Kawakami T, Yamasaki E, Sasaki R, Mizoguchi M. Linear scleroderma along Blaschko's lines in a patient with systematized morphea. Acta Derm Venereol 2003;83:362-4.
32. Vierra E, Cunningham BB. Morphea and localized scleroderma in children. Semin Cutan Med Surg 1999;18:210-25.
33. Kreuter A, Gambichler T, Avermaete A, et al. Combined treatment with calcipotriol ointment and low-dose ultraviolet A1 phototherapy in childhood morphea. Pediatr Dermatol 2001;18:241-5.
34. Kreuter A, Breuckmann F, Gambichler T, et al. Pulsed corticosteroid-methotrexate therapy for severe localized scleroderma. Pulsed high-dose corticosteroids combined with low-dose methotrexate in severe localized scleroderma. Arch Dermatol 2005;141:847-52.